25.12
Agenti ipoglicemizzanti orali: glinidi
La repaglinide (Prandin) e la nateglinide (Starlix), note come glinidi, sono secretagoghi orali dell'insulina che stimolano il rilascio di insulina da…
I glinidi sono secretagoghi dell'insulina che innescano il rilascio di insulina dalle cellule β inibendo i canali KATP e controllando l'efflusso di potassio.
Condividono due siti di legame con le sulfoniluree e un unico sito di legame.
Un farmaco, la repaglinide, ha un'insorgenza rapida dell'azione, con effetti più brevi che durano da quattro a sette ore.
Controlla efficacemente i picchi di glucosio postprandiali se assunto prima dei pasti.
La repaglinide può essere utilizzata nei pazienti con insufficienza renale e negli anziani. Può essere un trattamento autonomo o combinato con biguanidi.
Poiché è privo di zolfo, può essere utilizzato nei pazienti diabetici di tipo 2 con gravi allergie allo zolfo o alla sulfonilurea.
La nateglinide, un altro agente, stimola la secrezione di insulina più rapidamente ma con un'azione meno sostenuta rispetto ad altri agenti ipoglicemizzanti.
Questi farmaci mostrano effetti avversi, incluso il rischio ipoglicemico se i pasti vengono ritardati, saltati o a basso contenuto di carboidrati.
View the full transcript and gain access to JoVE Core videos
Q1: How do glinides work to lower blood glucose in type 2 diabetes?
Glinides are insulin secretagogues that trigger insulin release from pancreatic β cells by inhibiting ATP-sensitive potassium channels (KATP channels) and controlling potassium efflux. They share two binding sites with sulfonylureas and possess one unique binding site, enabling overlapping yet distinct mechanisms of action for glucose control.
Q2: What are the key differences between repaglinide and nateglinide?
Repaglinide has a rapid onset with a 4-7 hour duration, effectively controlling postprandial glucose spikes when taken before meals. Nateglinide stimulates insulin secretion more rapidly but with less sustained action than other agents, potentially causing fewer hypoglycemic episodes while maintaining similar secondary failure rates.
Q3: When should glinides be taken, and why is meal timing important?
Glinides should be taken shortly before meals to effectively manage post-meal glucose spikes. Hypoglycemia risk increases significantly if meals are delayed, skipped, or low in carbohydrates, making proper meal timing and composition critical for safe and effective use of these agents.
Q4: Which patients are suitable candidates for repaglinide therapy?
Repaglinide is suitable for elderly patients and those with renal impairment, as it is primarily metabolized by the liver with minimal kidney involvement. It can also be used in type 2 diabetic patients with severe sulfur or sulfonylurea allergies since it lacks sulfur, and can be combined with biguanides.
Q5: What is the primary adverse effect of glinides, and how does it develop?
The major adverse effect of glinides is hypoglycemia, which develops when insulin secretion occurs without adequate carbohydrate intake. Risk increases if meals are delayed, skipped, or contain insufficient carbohydrates, making patient education about meal timing and composition essential for safe therapy.
Q6: How are repaglinide and nateglinide metabolized, and what clinical implications does this have?
Repaglinide is rapidly absorbed, reaching peak blood levels within an hour and is mainly metabolized by the liver with minimal kidney processing. Nateglinide is metabolized primarily by hepatic enzymes and should be used cautiously in patients with liver insufficiency, as hepatic impairment can alter drug metabolism.
Q7: Can drug interactions affect glinide effectiveness, and what should clinicians monitor?
Yes, certain drugs may enhance glinide action by altering metabolism or displacing them from plasma protein-binding sites, increasing hypoglycemia risk. Conversely, some medications may reduce the glucose-lowering effect of nateglinide. Clinicians should monitor blood glucose levels closely when glinides are combined with other medications.